Researchers studied cost data for OC/OP/SG cancer patients compared with costs for patients without this type of cancer. They found total annual healthcare spending for OC/OP/SG patients with commercial insurance one year after diagnosis was $79,151 compared with $7,419 for people without OC/OP/SG cancer, indicating the cost burden of oral cancer was $71,732 for these patients. The cost burden was $35,890 for Medicare patients and $44,541 for Medicaid patients.
The authors suggested the cost of treatment for OC/OP/SG cancer may be the highest compared with costs for other cancers, which range from $31,559 to $65,123, according to other studies the authors cited.
More Articles on Cancer Costs:
Medical Oncologists’ Reimbursement Incentivizes Choosing High-Cost Meds
Study: Cancer Patients’ Higher Survival in U.S. vs. Europe “Worth” the Extra Costs
Study: Chemotherapy Patient Care Costs 24% More in Hospital Outpatient Setting Than in Physician Office
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
